• Who we are

Leadership Team

Nicolas Fischer, CEO

nicolas fischer

After obtaining a PhD in molecular biology, Nicolas joined the group of Greg Winter (2018 Nobel prize for chemistry) at the Medical Research Council in Cambridge (UK) to work on in vitro evolution of proteins and antibody engineering.

At Novimmune since 2002, he led several therapeutic antibody programs. Then, as the Head of Research, he focused on the development of the κλ body bispecific antibody platform which is now the core technology of Light Chain Bioscience.

Back

First patient dosed with NILK-2301 in Phase I clinical trial

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer


Read more

LinkedIn